Kenvue Inc. (NYSE:KVUE) Shares Bought by Assetmark Inc.

Assetmark Inc. grew its position in Kenvue Inc. (NYSE:KVUE) by 29.9% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 67,796 shares of the company’s stock after acquiring an additional 15,593 shares during the quarter. Assetmark Inc.’s holdings in Kenvue were worth $1,568,000 at the end of the most recent reporting period.

Other large investors have also modified their holdings of the company. Riverview Trust Co acquired a new stake in Kenvue during the 3rd quarter worth $30,000. Deseret Mutual Benefit Administrators boosted its stake in shares of Kenvue by 49.7% during the third quarter. Deseret Mutual Benefit Administrators now owns 1,960 shares of the company’s stock worth $45,000 after buying an additional 651 shares during the period. Studio Investment Management LLC grew its holdings in shares of Kenvue by 52.1% during the second quarter. Studio Investment Management LLC now owns 2,468 shares of the company’s stock worth $45,000 after buying an additional 845 shares during the last quarter. AlphaMark Advisors LLC purchased a new position in shares of Kenvue during the third quarter worth about $77,000. Finally, Loring Wolcott & Coolidge Fiduciary Advisors LLP MA acquired a new position in Kenvue in the 2nd quarter valued at about $61,000. 97.64% of the stock is owned by institutional investors and hedge funds.

Kenvue Trading Up 2.0 %

Shares of KVUE opened at $23.61 on Friday. Kenvue Inc. has a twelve month low of $17.67 and a twelve month high of $23.95. The company has a current ratio of 1.00, a quick ratio of 0.69 and a debt-to-equity ratio of 0.66. The firm has a market capitalization of $45.27 billion, a P/E ratio of 42.62, a PEG ratio of 2.15 and a beta of 1.36. The firm’s 50-day moving average is $22.73 and its two-hundred day moving average is $20.63.

Kenvue (NYSE:KVUE) last released its quarterly earnings results on Thursday, November 7th. The company reported $0.28 earnings per share for the quarter, topping analysts’ consensus estimates of $0.27 by $0.01. Kenvue had a return on equity of 21.43% and a net margin of 6.88%. The business had revenue of $3.90 billion for the quarter, compared to analysts’ expectations of $3.92 billion. During the same quarter in the prior year, the firm posted $0.31 EPS. The company’s revenue was down .4% compared to the same quarter last year. On average, research analysts predict that Kenvue Inc. will post 1.07 earnings per share for the current fiscal year.

Kenvue Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Wednesday, November 27th. Stockholders of record on Wednesday, November 13th will be given a $0.205 dividend. This represents a $0.82 dividend on an annualized basis and a dividend yield of 3.47%. The ex-dividend date is Wednesday, November 13th. Kenvue’s dividend payout ratio is currently 149.09%.

Analyst Ratings Changes

A number of research firms have weighed in on KVUE. Bank of America increased their price objective on Kenvue from $24.00 to $27.00 and gave the stock a “buy” rating in a research report on Tuesday, October 22nd. Deutsche Bank Aktiengesellschaft increased their price target on Kenvue from $23.00 to $24.00 and gave the stock a “buy” rating in a report on Wednesday, August 7th. JPMorgan Chase & Co. boosted their price objective on shares of Kenvue from $24.00 to $25.00 and gave the company an “overweight” rating in a research note on Friday, October 11th. Jefferies Financial Group initiated coverage on shares of Kenvue in a research note on Tuesday, September 24th. They issued a “buy” rating and a $27.00 target price for the company. Finally, UBS Group lifted their target price on shares of Kenvue from $20.00 to $22.00 and gave the company a “neutral” rating in a report on Wednesday, August 7th. One investment analyst has rated the stock with a sell rating, seven have issued a hold rating and four have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $22.64.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.